10-QPeriod: Q1 FY2002

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2002

Filed May 15, 2002For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $22.1 million for the first quarter of 2002, compared to a net loss of $38.1 million in the prior year period. This improvement is largely due to a significant non-cash charge of $25.9 million related to a change in accounting principle for revenue recognition in Q1 2001, as well as reduced merger-related costs. Total revenues increased by 16.4% to $40.7 million, driven by higher product sales and collaborative R&D revenues, particularly from the Novartis collaboration. The company continues to invest heavily in research and development, with expenses rising to $47.0 million from $32.5 million year-over-year, reflecting its commitment to advancing its pipeline of drug candidates across various therapeutic areas. Despite the ongoing losses, Vertex maintains a strong liquidity position with approximately $699 million in cash and marketable securities as of March 31, 2002. The company's operations are funded through a combination of strategic collaborations, product revenues, and its existing cash reserves. Vertex is actively managing its expenses and expects R&D and administrative costs to continue to increase as it advances its pipeline. The company also faces ongoing legal proceedings related to patent infringement claims and inventorship disputes, which it believes are without merit and intends to defend vigorously.

Key Highlights

  • 1Reported a net loss of $22.1 million for Q1 2002, an improvement from the $38.1 million net loss in Q1 2001, aided by a prior year accounting charge and reduced merger costs.
  • 2Total revenues grew by 16.4% year-over-year to $40.7 million, driven by a 32% increase in product sales and a 16% rise in collaborative R&D revenues.
  • 3Research and Development (R&D) expenses increased significantly by 44.5% to $47.0 million, reflecting continued investment in drug pipeline advancement.
  • 4The company holds a robust cash and marketable securities position totaling $699 million as of March 31, 2002, providing ample liquidity for operations and R&D.
  • 5Agenerase (amprenavir), an HIV protease inhibitor, continues to be a key revenue driver through royalties.
  • 6Vertex is engaged in two ongoing legal proceedings related to patent infringement and inventorship, which the company intends to defend vigorously.
  • 7The company has realigned its business segments into 'Pharmaceuticals' and 'Discovery Tools and Services'.

Frequently Asked Questions

For the first quarter ended March 31, 2002, Vertex reported a net loss of $22.1 million, or $0.29 per share. This represents an improvement compared to the net loss of $38.1 million, or $0.52 per share, in the same period of 2001. Total revenues increased to $40.7 million from $34.9 million.

Revenue growth was fueled by a 32% increase in product sales within the Discovery Tools and Services segment, primarily due to technology licensing revenue from the Pfizer contract, and a 16% rise in collaborative and other research and development revenues, notably from the Novartis collaboration.

Vertex maintained a strong liquidity position with $699 million in cash and marketable securities as of March 31, 2002. While net cash used in operations was $30.3 million for the quarter, the company's funding strategy relies on strategic collaborations, product sales, royalties, and existing cash reserves. They expect to finance future cash needs through these sources and potentially additional financing if required.

Research and development expenses increased significantly to $47.0 million from $32.5 million in the prior year. This investment supports the advancement of drug candidates in areas such as infectious diseases (HIV, Hepatitis C), inflammation and autoimmune diseases (Rheumatoid Arthritis, Psoriasis), and cancer. Key collaborations are with GlaxoSmithKline, Eli Lilly, Aventis, and Novartis.